drugset / Trial / NCT07855133

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

NCT07855133 ↗

Phase 1 Not yet recruiting 60 enrolled Novo Nordisk A/S
NaSequentialOpen-labelTreatment

Summary

The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.

Timeline

Start
2026-09-30
Primary completion
2028-09-06
Completion
2028-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide — Subcutaneous
Subject Zenagamtide Unknown — Subcutaneous